Longaeva Partners’s Neuropace NPCE Stock Holding History

Longaeva Partners’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,933	Closed	-$122K	–	88
2025 Q2	$122K	Sell	10,933 -89,052	-89%	-$1.11M	0.02%	53
2025 Q1	$1.23M	Buy	+99,985	New	+$1.25M	0.7%	16

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

KLP

Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Longaeva Partners's NPCE Position: Q3 2025 in Review

Longaeva Partners sold out of Neuropace (NPCE) in Q3 2025, closing a stake of 10,933 shares — an estimated $122K sold.

Longaeva Partners first reported a position in NPCE in Q1 2025 and held it in 2 quarters. The position peaked at $1.23M in Q1 2025. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

Longaeva Partners reported no remaining Neuropace position as of Q3 2025 after selling out during the quarter.
Longaeva Partners sold 10,933 Neuropace shares in Q3 2025, an estimated $122K.
Longaeva Partners first reported a position in Neuropace in Q1 2025 and held it in 2 quarters.
Longaeva Partners's Neuropace position peaked at $1.23M in Q1 2025.
80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on Longaeva Partners's 13F filing for Q3 2025, filed 14 Nov 2025.